FOQUEST Receives Approval for Expanded Indication for Children and Adolescents with ADHD

Purdue Pharma (Canada) announced today that Health Canada has issued a Notice of Compliance (NOC) for an expanded indication for FOQUEST® (methylphenidate HCl controlled-release capsules), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents six years of age and older.¹ This announcement follows the December 6, 2017 Notice of Compliance for FOQUEST for the treatment of ADHD in adults 18 years of age and older.²  

FOQUEST is the first methylphenidate product approved in Canadathat provides ADHD patients with symptom control throughout the day, and an onset of action within one hour.³

"In clinical trials with children and adolescent patients, it was shown that FOQUEST demonstrated significant improvements in ADHD symptoms such as inattentiveness, hyperactivity and impulsivity," said Dr. Roxanne Goldade, Community Pediatrician and Chief of the Section of Community Paediatrics in the Department of Paediatrics at the University of Calgary. "As a fast-acting, longer lasting methylphenidate formulation, this provides an additional treatment option that can be a valuable part of a comprehensive management program for younger Canadians living with ADHD."

A neurobiological disorder that results in difficulty regulating attention, impulsiveness and/or hyperactivity,^4,5 ADHD affects approximately 5-9 per cent of Canadian children. Students with ADHD are at a higher risk for lower academic achievement, grade retention, special education, disciplinary referrals and dropping out of high school.⁶

"Today's news is an exciting development for young Canadians and their families who now have a new option to help manage their ADHD," said Purdue Pharma (Canada) President and CEO David Pidduck. "We are particularly proud of this milestone because FOQUEST was researched and developed here in Canada and is a great example of how Canadian innovation is helping to improve quality of life for those living with ADHD."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.